Ustekinumab in treatment of Crohn’s disease: Design, development, and potential place in therapy

Parakkal Deepak, Edward Vincent Loftus, Jr

Research output: Contribution to journalReview article

24 Citations (Scopus)

Abstract

Crohn’s disease is characterized by a dysregulation of both innate and adaptive immunity responses. Interleukin-12/23 (IL-12/23) pathway has been found to be a major driver of inflammation in adaptive immune responses. Ustekinumab is a fully human immunoglobulin G1 kappa monoclonal antibody that blocks the p40 subunit of IL-12 and IL-23 and prevents their interaction with their cell surface receptor and further cytokine activation. It is currently approved in the management of plaque psoriasis and psoriatic arthritis. Very promising data have emerged through phase II and phase III trials (UNITI-1, UNITI-2, and IM-UNITI) for both induction and maintenance of clinical response and remission in moderate-to-severe Crohn’s disease, resulting in approval by the Food and Drug Administration for this condition. This article reviews the immunology of the IL-12/23 pathway, available data regarding the initial designing of ustekinumab, drug development through clinical trials including pharmacokinetics, efficacy, and safety, and its potential place in the treatment of Crohn’s disease.

Original languageEnglish (US)
Pages (from-to)3685-3698
Number of pages14
JournalDrug Design, Development and Therapy
Volume10
DOIs
StatePublished - Nov 11 2016

Fingerprint

Interleukin-23
Interleukin-12
Crohn Disease
Adaptive Immunity
Psoriatic Arthritis
Cell Surface Receptors
United States Food and Drug Administration
Allergy and Immunology
Psoriasis
Innate Immunity
Immunoglobulins
Therapeutics
Pharmacokinetics
Monoclonal Antibodies
Maintenance
Clinical Trials
Cytokines
Inflammation
Safety
Pharmaceutical Preparations

Keywords

  • Crohn’s disease
  • Inflammatory bowel disease
  • Interleukin-12
  • Interleukin-12/23 monoclonal antibody
  • Interleukin-23
  • Ustekinumab

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science
  • Drug Discovery

Cite this

Ustekinumab in treatment of Crohn’s disease : Design, development, and potential place in therapy. / Deepak, Parakkal; Loftus, Jr, Edward Vincent.

In: Drug Design, Development and Therapy, Vol. 10, 11.11.2016, p. 3685-3698.

Research output: Contribution to journalReview article

@article{a146930aab1d419f8604daa1a2de9db5,
title = "Ustekinumab in treatment of Crohn’s disease: Design, development, and potential place in therapy",
abstract = "Crohn’s disease is characterized by a dysregulation of both innate and adaptive immunity responses. Interleukin-12/23 (IL-12/23) pathway has been found to be a major driver of inflammation in adaptive immune responses. Ustekinumab is a fully human immunoglobulin G1 kappa monoclonal antibody that blocks the p40 subunit of IL-12 and IL-23 and prevents their interaction with their cell surface receptor and further cytokine activation. It is currently approved in the management of plaque psoriasis and psoriatic arthritis. Very promising data have emerged through phase II and phase III trials (UNITI-1, UNITI-2, and IM-UNITI) for both induction and maintenance of clinical response and remission in moderate-to-severe Crohn’s disease, resulting in approval by the Food and Drug Administration for this condition. This article reviews the immunology of the IL-12/23 pathway, available data regarding the initial designing of ustekinumab, drug development through clinical trials including pharmacokinetics, efficacy, and safety, and its potential place in the treatment of Crohn’s disease.",
keywords = "Crohn’s disease, Inflammatory bowel disease, Interleukin-12, Interleukin-12/23 monoclonal antibody, Interleukin-23, Ustekinumab",
author = "Parakkal Deepak and {Loftus, Jr}, {Edward Vincent}",
year = "2016",
month = "11",
day = "11",
doi = "10.2147/DDDT.S102141",
language = "English (US)",
volume = "10",
pages = "3685--3698",
journal = "Drug Design, Development and Therapy",
issn = "1177-8881",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Ustekinumab in treatment of Crohn’s disease

T2 - Design, development, and potential place in therapy

AU - Deepak, Parakkal

AU - Loftus, Jr, Edward Vincent

PY - 2016/11/11

Y1 - 2016/11/11

N2 - Crohn’s disease is characterized by a dysregulation of both innate and adaptive immunity responses. Interleukin-12/23 (IL-12/23) pathway has been found to be a major driver of inflammation in adaptive immune responses. Ustekinumab is a fully human immunoglobulin G1 kappa monoclonal antibody that blocks the p40 subunit of IL-12 and IL-23 and prevents their interaction with their cell surface receptor and further cytokine activation. It is currently approved in the management of plaque psoriasis and psoriatic arthritis. Very promising data have emerged through phase II and phase III trials (UNITI-1, UNITI-2, and IM-UNITI) for both induction and maintenance of clinical response and remission in moderate-to-severe Crohn’s disease, resulting in approval by the Food and Drug Administration for this condition. This article reviews the immunology of the IL-12/23 pathway, available data regarding the initial designing of ustekinumab, drug development through clinical trials including pharmacokinetics, efficacy, and safety, and its potential place in the treatment of Crohn’s disease.

AB - Crohn’s disease is characterized by a dysregulation of both innate and adaptive immunity responses. Interleukin-12/23 (IL-12/23) pathway has been found to be a major driver of inflammation in adaptive immune responses. Ustekinumab is a fully human immunoglobulin G1 kappa monoclonal antibody that blocks the p40 subunit of IL-12 and IL-23 and prevents their interaction with their cell surface receptor and further cytokine activation. It is currently approved in the management of plaque psoriasis and psoriatic arthritis. Very promising data have emerged through phase II and phase III trials (UNITI-1, UNITI-2, and IM-UNITI) for both induction and maintenance of clinical response and remission in moderate-to-severe Crohn’s disease, resulting in approval by the Food and Drug Administration for this condition. This article reviews the immunology of the IL-12/23 pathway, available data regarding the initial designing of ustekinumab, drug development through clinical trials including pharmacokinetics, efficacy, and safety, and its potential place in the treatment of Crohn’s disease.

KW - Crohn’s disease

KW - Inflammatory bowel disease

KW - Interleukin-12

KW - Interleukin-12/23 monoclonal antibody

KW - Interleukin-23

KW - Ustekinumab

UR - http://www.scopus.com/inward/record.url?scp=84995684222&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995684222&partnerID=8YFLogxK

U2 - 10.2147/DDDT.S102141

DO - 10.2147/DDDT.S102141

M3 - Review article

C2 - 27956825

AN - SCOPUS:84995684222

VL - 10

SP - 3685

EP - 3698

JO - Drug Design, Development and Therapy

JF - Drug Design, Development and Therapy

SN - 1177-8881

ER -